Monoclonal antibodies against AMD inhibit tumor growth and enhance the antitumor effect exerted by temozolomide (in temozolomide-resistant glioma samples, overexpression of AMD has been reported); this inhibition has also been observed when the tetracyclic diterpenoid ester ingenol mebutate was administered by inhibiting the effects mediated by AMD [7,137]. This evidence concerns the gene AMD1 and central nervous system cancer.